Alunbrig Európai Unió - magyar - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - karcinóma, nem kissejtes tüdő - daganatellenes szerek - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.